Literature DB >> 27106862

Erratum to: Severe malaria in children leads to a significant impairment of transitory otoacoustic emissions - a prospective multicenter cohort study.

Joachim Schmutzhard1, Peter Lackner2, Raimund Helbok2, Helene Verena Hurth2, Fabian Cedric Aregger2, Veronika Muigg3,4, Josua Kegele2, Sebastian Bunk2, Lukas Oberhammer3,4, Natalie Fischer5, Leyla Pinggera5, Allan Otieno6, Bernards Ogutu6, Tsiri Agbenyega7, Daniel Ansong7, Ayola A Adegnika3,4, Saadou Issifou3,4, Patrick Zorowka8, Sanjeev Krishna9, Benjamin Mordmüller3,4, Erich Schmutzhard2, Peter Kremsner3,4.   

Abstract

Entities:  

Year:  2016        PMID: 27106862      PMCID: PMC4841951          DOI: 10.1186/s12916-016-0616-4

Source DB:  PubMed          Journal:  BMC Med        ISSN: 1741-7015            Impact factor:   8.775


× No keyword cloud information.

Erratum

After publication of the original article [1], it came to the authors’ attention that a source of funding for the clinical trial was inadvertently omitted from the Acknowledgement section. The European and Developing Countries Clinical Trials Partnership (EDCTP) should have been mentioned as a part funder, so the Acknowledgement section should have read as follows:
  1 in total

1.  Severe malaria in children leads to a significant impairment of transitory otoacoustic emissions--a prospective multicenter cohort study.

Authors:  Joachim Schmutzhard; Peter Lackner; Raimund Helbok; Helene Verena Hurth; Fabian Cedric Aregger; Veronika Muigg; Josua Kegele; Sebastian Bunk; Lukas Oberhammer; Natalie Fischer; Leyla Pinggera; Allan Otieno; Bernards Ogutu; Tsiri Agbenyega; Daniel Ansong; Ayola A Adegnika; Saadou Issifou; Patrick Zorowka; Sanjeev Krishna; Benjamin Mordmüller; Erich Schmutzhard; Peter Kremsner
Journal:  BMC Med       Date:  2015-05-28       Impact factor: 8.775

  1 in total
  1 in total

Review 1.  Cerebral Malaria: Current Clinical and Immunological Aspects.

Authors:  Karin Albrecht-Schgoer; Peter Lackner; Erich Schmutzhard; Gottfried Baier
Journal:  Front Immunol       Date:  2022-04-20       Impact factor: 8.786

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.